Bevacizumab
- Generic Name
- Bevacizumab
- Brand Names
- Avastin, Mvasi, Oyavas, Alymsys, Aybintio, Abevmy, Vegzelma, Onbevzi, Zirabev, Lytenava, Avzivi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 216974-75-3
- Unique Ingredient Identifier
- 2S9ZZM9Q9V
- Background
There is a great deal of evidence indicating that vascular endothelial growth factor (VEGF) is important for the survival and proliferation of cancer cells. VEGF plays an important role in angiogenesis, lymphangiogenesis, and tumor growth, which are all factors that contribute to its attractiveness as a therapeutic target for anti-cancer therapies.
...
- Indication
As a vascular endothelial growth factor (VEGF) inhibitor, bevacizumab is used in several chemotherapy regimens to treat metastatic colorectal cancer; metastatic, unresectable, locally advanced or recurrent non-squamous non-small cell lung cancer; metastatic renal cell carcinoma; metastatic, persistent, or recurrent cervical cancer; primary peritoneal cancer;...
- Associated Conditions
- Metastatic Breast Cancer, Metastatic Cervical Cancer, Metastatic Colorectal Cancer (CRC), Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Renal Cell Carcinoma ( mRCC), Persistent Cervical Cancer, Recurrent Cervical Cancer, Recurrent Glioblastoma, Relapsed Glioblastoma, Stage III Fallopian Tube Cancer, Stage III Ovarian Epithelial Cancer, Stage III Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Primary Peritoneal Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent Non-Squamous Non-Small Cell Lung Cancer, Recurrent Platinum-Sensitive Epithelial Ovarian Cancer, Recurrent Platinum-resistant Epithelial Ovarian Cancer, Recurrent platinum drug resistant Fallopian tube cancer, Recurrent platinum drug resistant primary peritoneal cancer, Recurrent platinum sensitive primary peritoneal cancer, Recurrent platinum-sensitive fallopian tube cancer, Unresectable Non-Squamous Non-Small Cell Lung Cancer, Unresectable, advanced Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
- Associated Therapies
- First Line Chemotherapy, First or Second Line Therapy, Second Line Treatment
Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2015-04-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00253526
Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-11-11
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- US Oncology Research
- Target Recruit Count
- 247
- Registration Number
- NCT00252564
- Locations
- 🇺🇸
Melbourne Internal Medicine Associates, Melbourne, Florida, United States
🇺🇸Maryland Oncology Hematology, P.A., Columbia, Maryland, United States
🇺🇸Hematology Oncology Associates of Ohio & Michigan, Lambertville, Michigan, United States
Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-10-07
- Last Posted Date
- 2016-03-14
- Lead Sponsor
- Christopher Sweeney, MBBS
- Target Recruit Count
- 45
- Registration Number
- NCT00234494
- Locations
- 🇺🇸
Northern Indiana Cancer Research Consortium, South Bend, Indiana, United States
🇺🇸Siteman Cancer Center, St. Louis, Missouri, United States
🇺🇸Indiana University Cancer Center, Indianapolis, Indiana, United States
Phase 2 Trial of Bevacizumab in Combination With Pemetrexed
- Conditions
- Interventions
- First Posted Date
- 2005-09-27
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- Heather Wakelee
- Target Recruit Count
- 16
- Registration Number
- NCT00227019
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
🇺🇸Norris Cotton Cancer Center, Lebanon, New Hampshire, United States
🇺🇸Cooper Cancer Institute, Voorhees, New Jersey, United States
Combination Chemotherapy for 1st Line Treatment of Advanced or Metastatic Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2008-07-09
- Lead Sponsor
- University of Oklahoma
- Target Recruit Count
- 50
- Registration Number
- NCT00222469
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸University of Oklahoma, Oklahoma City, Oklahoma, United States
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 3610
- Registration Number
- NCT00217737
- Locations
- 🇺🇸
UM Saint Joseph Medical Center, Towson, Maryland, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Saint Luke's Hospital, Maumee, Ohio, United States
Study of Pemetrexed and Bevacizumab in Patients With Head and Neck Cancer
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2016-02-15
- Lead Sponsor
- University of Pittsburgh
- Target Recruit Count
- 42
- Registration Number
- NCT00222729
- Locations
- 🇺🇸
Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Primary Systemic Therapy in Operable/Locally Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2016-05-11
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 40
- Registration Number
- NCT00203502
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Bevacizumab Plus Capecitabine (Xeloda) in Patients With Untreated Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2017-02-06
- Lead Sponsor
- Translational Oncology Research International
- Target Recruit Count
- 45
- Registration Number
- NCT00203411
- Locations
- 🇺🇸
Virginia K. Crosson Cancer Center, Fullerton, California, United States
🇺🇸UCLA Medical Center, Los Angeles, California, United States
🇺🇸Santa Barbara Hematology Oncology Medical Group, Inc., Santa Barbara, California, United States
Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2013-01-31
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 94
- Registration Number
- NCT00193258
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.